• Products
  • Insights
  • Practice Management
  • Resources
  • About Us

Domestic Equity fund

Hartford Healthcare Fund   

Domestic Equity fund

Hartford Healthcare Fund   
Share Class - R5 (HGHTX)

Opportunistic

 

Seeks to capitalize on the demographics, globalization, and innovation opportunities in the global-health care market

Best Ideas

 

Uses in-depth research to create a portfolio with the best ideas from portfolio managers and analysts

Sub-advised by Wellington

 

Wellington prioritizes independent thought and collaboration across all major asset classes

Objective: Seeks long-term capital appreciation.

Portfolio Management
Senior Managing Director
Global Industry Analyst
5
YRS
MANAGING THIS FUND
18
YRS
AT WELLINGTON MANAGEMENT
20
YRS
EXPERIENCE IN THIS INDUSTRY

The portfolio manager is supported by the full resources of Wellington.

Performance

PERFORMANCE %
 
CUMULATIVE %
(as of 10/31/2025)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 10/31/2025)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare R5 6.59 -0.29 4.63 4.15 7.27 10.57
Benchmark 5.77 -0.09 4.36 8.53 9.19 ---
Morningstar Health Category 13.07 6.98 6.13 4.58 7.19 ---
 
CUMULATIVE %
(as of 9/30/2025)
AVERAGE ANNUAL TOTAL RETURNS %
(as of 9/30/2025)
YTD 1YR 3YR 5YR 10YR SI
Hartford Healthcare R5 0.40 -11.29 5.09 2.44 7.32 10.35
Benchmark 2.21 -7.83 6.33 7.08 9.59 ---
Morningstar Health Category 6.52 -2.72 6.30 2.76 6.96 ---

Performance data quoted represents past performance and does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than their original cost. Current performance may be lower or higher than the performance data quoted.

SI = Since Inception. Fund Inception: 05/01/2000

Share Class Inception: 12/22/06.
Class R5-share performance prior to its inception date reflects Y-share performance and operating expenses. SI performance is calculated from 5/1/00.

Hartford Healthcare Fund R5 Share Morningstar Ratings
Morningstar Medalist RatingTM
9/23/2025

Characteristics

FUND ESSENTIALS(as of 10/31/2025)
Inception Date 05/01/2000
Net Assets $799 million
Total Operating Expenses 1.04%
Morningstar Category Health
Lipper Classification Health/Biotechnology Funds
CUSIP 41664L302
Fund Number 1356
FUND STATS (as of 10/31/2025)
# of Holdings
77
% in Equities
99
% in Foreign Equities
9
Beta (3 year)
1.03
R Squared (3 year)
0.92
Standard Deviation
13.72%
Turnover
40%
Active Share
42%
Holdings Characteristics (as of 10/31/2025)
FUND S&P Composite 1500 Health Care Index
Price/Earnings
27.2x 16.7x
Price/Book
5.2x 4.9x
EPS Growth Rate
8.6% 8.9%
Asset Weighted Market Cap (billions)
$223.6 $251.2
Return on Equity
20.8% 33.1%
Median Market Cap (billions)
$11.1 $7.6
Regional Exposure (%)
North America 91
Developed EU & Middle East ex UK 6
United Kingdom 3
Emerging Markets 0
North America 90
Developed EU & Middle East ex UK 6
United Kingdom 3
Japan 1
Emerging Markets 0
Top Ten Holdings (%) (as of 10/31/2025)
Eli Lilly & Co. 12.89
UnitedHealth Group, Inc. 5.84
AbbVie, Inc. 4.70
Johnson & Johnson 4.48
Merck & Co., Inc. 4.22
Intuitive Surgical, Inc. 3.94
Vertex Pharmaceuticals, Inc. 3.21
Boston Scientific Corp. 3.10
Edwards Lifesciences Corp. 3.03
Cencora, Inc. 3.01
Total Portfolio % 48.42
Market Cap Distribution (%) (as of 10/31/2025)

Market Cap Header3

Less than $2 billion 4
$2 billion - $5 billion 7
$5 billion - $10 billion 5
Greater than $10 billion 84
Not Classified 0
RETURN CHARACTERISTICS (as of 10/31/25)
Alpha (5 Year)
-3.97
Down Capture (5 Year)
108.63
Information Ratio (5 Year)
-0.91
Sharpe Ratio (5 Year)
0.13
Up Capture (5 Year)
89.94
Subsector Exposure (%)
Biopharma Large Cap 38
Medical Technology 28
Health Care Services 18
Biopharma Mid Cap 13
Biopharma Small Cap 4
Biopharma Large Cap 40
Medical Technology 26
Health Care Services 18
Biopharma Mid Cap 13
Biopharma Small Cap 3
Based on sub-adviser's classification of health care subsectors, which includes combining biotechnology and pharmaceuticals in terms of capitalization: biopharma small-cap, biopharma mid-cap, and biopharma large-cap. Excludes cash. May not total to 100% due to rounding.
distributions and capital gains
Distribution Date Distribution NAV ordinary income short term capital gains long term capital gains total distribution
12/27/2024 42.88 $0.0737 $0.0000 $0.0000 $0.0737
12/11/2024 44.31 $0.0000 $0.6470 $1.2516 $1.8986
Past distributions are not indicative of future distributions.

Resources

Important Risks: Investing involves risk, including the possible loss of principal. Security prices fluctuate in value depending on general market and economic conditions and the prospects of individual companies. • Risks of focusing investments on the healthcare related sector include regulatory and legal developments, changes in funding or subsidies, patent and intellectual property considerations, intense competitive pressures, rapid technological changes, long and costly process for obtaining product approval by government agencies, potential product obsolescence, rising cost of medical products and services, and price volatility risk. • Small- and mid-cap securities can have greater risks and volatility than large-cap securities. • The securities of large market capitalization companies may underperform other segments of the market. • Foreign investments may be more volatile and less liquid than U.S. investments and are subject to the risk of currency fluctuations and adverse political, economic and regulatory developments.
4517824